Phase I/II studies demonstrate safety and effectiveness of daraxonrasib for pancreatic ductal adenocarcinoma, suggesting future treatment potential.
Results from two separate phase I/II studies investigating the pan-RAS inhibitor daraxonrasib suggest it is safe and effective for patients with pancreatic ductal adenocarcinoma, building on recently announced data showcasing the drug's superior performance in a phase III study. Together, these new data are an exciting sign that daraxonrasib could become the first targeted pancreatic cancer therapy to spur sustained responses.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: